New imaging technique enhances tumor and nerve visualization in HNSCC surgery

Head and neck squamous cell carcinoma (HNSCC) ranks as one of the most common cancers globally, with over 650,000 new cases reported each year.

JAK Inhibitor Comes Up Short in Phase III Crohn’s Disease Trial

An investigational oral Janus kinase (JAK) inhibitor failed to meet most primary endpoints in a phase III trial of patients with moderate to severe Crohn’s

December 7, 2024

Surgery May Be More Cost-Effective Than Wegovy in Adults With a BMI 35+

A certain type of bariatric surgery may prove more cost-effective over time than a popular weight loss drug, an economic evaluation study suggested. In an

April 13, 2024

AstraZeneca-Daiichi Sankyo’s gastric cancer therapy approved

AstraZeneca and Daiichi Sankyo’s Enhertu achieved a confirmed ORR of 28.8% and a median PFS of 5.7 months. Credit: Robert Way/Shutterstock. AstraZeneca and Daiichi Sankyo‘s

August 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.